Welcome to TROPHOS
Trophos is an advanced clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with greatly under-served needs in neurology and cardiology.
In March 2014, Trophos announced encouraging top line results (en franšais ici) from a pre-registration trial of olesoxime for the treatment of Spinal Muscular Atrophy. We are now focusing on seeking approval for olesoxime from regulators. If approved, olesoxime would be the first ever treatment specifically developed and approved for SMA. Approval of the product expected in 2016.(More information here).